Advances in the Treatment of Pulmonary Hypertension and Pulmonary Embolism
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: 30 October 2024 | Viewed by 51
Special Issue Editors
Interests: pulmonary hypertension; pulmonary embolism; clinical cardiology; echocardiography; metabolism
Special Issues, Collections and Topics in MDPI journals
Interests: pulmonary hypertension; pulmonary embolism; interventional cardiology; echocardiography
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In your opinion, is pulmonary hypertension a rare disease? Furthermore, is pulmonary embolism a serious disease? Your answer would probably be immediately affirmative, but things are more complex! In fact, when we face and treat these two diseases, many doubts still accompany our decisions. For example, which initial treatment is preferable in the patient with newly diagnosed pulmonary hypertension? “Can we” or “should we” start with two drugs right away? If the patient has many comorbidities, how do we manage it?
Moreover, if a patient presents an acute pulmonary embolism with severe hemodynamic compromise, what type of thrombolysis do we perform (systemic or local)? If thrombolysis is not possible, should we ask for the intervention of a cardiac surgeon or interventional cardiologist?
The purpose of this Special Issue is to attempt finding the answers to these and other questions on the therapeutic management of patients with pulmonary hypertension or pulmonary embolism, based on the most recent and interesting scientific evidence.
Topics which will be welcomed in this Special Issue of Life include, but are not limited to, the following:
- Treatment of pulmonary arterial hypertension;
- Future therapeutic perspectives of pulmonary arterial hypertension;
- Treatment of groups 2, 3, and 4 pulmonary hypertension;
- Treatment of acute pulmonary embolism;
- Prevention of pulmonary embolism recurrence;
- Percutaneous treatment of high-risk acute pulmonary embolism;
- Artificial intelligence (AI) and machine learning applications.
Dr. Egidio Imbalzano
Dr. Marco Vatrano
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary hypertension
- pulmonary embolism
- therapy
- cardiac imaging
- artificial intelligence
